ArticleInternational journal of surgery (London, England)2026
A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal therapy.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer remains one of the deadliest malignancies with poor survival outcomes. This study investigated the influence of evolving multimodal strategies, particularly the increased use of neoadjuvant chemotherapy (NAC) and extended surgical resection, on patient outcomes over the last decade. Methods: This before-and-after study included patients with pancreatic cancer who received curative surgery at a tertiary medical center from 2011 to 2022. The patients were divided into two treatment periods: Period A (2011-2017, Results: NAC use increased significantly from 22.1% in period A to 74.9% in period B ( Conclusion: The shift toward a multimodal approach significantly improved survival in patients with pancreatic cancer, especially those with resectable and borderline resectable tumors. Although extended pancreatectomy increases surgical risk, the survival benefits support its selective use. Continued refinement of the treatment selection and perioperative care is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.